Flow Pharma

About Flow Pharma

Flow Pharma, Inc. is a biopharmaceutical company that leverages artificial intelligence for the development of immunotherapies aimed at treating cancers and preventing viral diseases. Founded in 1999 by Dr. Reid Rubsamen, who currently serves as CEO, the company operates from its headquarters in Cleveland, Ohio. Dr. Rubsamen's background combines computer science degrees from UC Berkeley and Stanford with a medical degree from Stanford, a residency at Massachusetts General Hospital, and extensive experience in biopharmaceuticals, holding over 70 U.S. patents.

The company's core technology is the FlowVax™ platform, which is engineered to stimulate a patient's own T-cells to target and attack cancer cells and virus-infected cells. This is achieved by first using AI to identify specific neoantigen peptide targets on these cells. These peptides are then synthesized and loaded onto microspheres designed to be the same size as human white blood cells, a patented approach called Size Exclusion Antigen Presentation Control (SEAPAC™). This method is designed to teach the immune system to recognize and eliminate harmful cells, leaving healthy ones undamaged. The therapies can be administered through various methods, including injection and inhalation.

Flow Pharma's pipeline includes several therapeutic candidates. For oncology, it is developing FlowVax BreastCA for treatment-resistant breast cancers, such as triple-negative breast cancer, and FlowVax HPV to address cancers caused by the human papillomavirus. In the realm of infectious diseases, the company has developed FLOVID-20, a COVID-19 immunotherapy that has undergone pre-clinical testing, and a vaccine for Ebola/Marburg, developed under contract with the U.S. Department of Defense. Flow Pharma's business model appears to be centered on the research, development, and eventual commercialization of these therapeutic vaccines. The company has secured funding through various rounds, totaling over $3.8 million, with investors including Button Capital and government bodies like the U.S. Department of Defense.